Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2025 06:01 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif.,...
October 07, 2025 07:00 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
August 28, 2025 07:00 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
August 14, 2025 18:30 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
August 08, 2025 07:15 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically...
June 03, 2025 07:00 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
May 28, 2025 07:00 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with...
May 12, 2025 07:00 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two...
May 11, 2025 03:21 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l’essai de phase IIb HARMONY lors de présentations orales et d’affiches lors du congrès 2025 de l’EASL

L’analyse des résultats de l’EFX au moyen de la pathologie numérique basée sur l’IA souligne le potentiel d’évaluation de la réponse histopathologique Ces données s’ajoutent au nombre croissant de...
May 11, 2025 03:21 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase-IIb-Studie HARMONY in Vorträgen und Postern auf dem EASL-Kongress 2025

Die Analyse der Ergebnisse zu EFX mit KI-basierter digitaler Pathologie unterstreicht den potenziellen Wert bei der Bewertung des histopathologischen Ansprechens Die Daten tragen dazu bei, dass die...